Prosecution Insights
Last updated: October 21, 2026
Application No. 18/968,265

LAGENIDIUM JURACYAE WITH BURSAPHELENCHUS XYLOPHILUS (B. XYLOPHILUS)-KILLING ACTIVITY AND USE THEREOF IN CONTROL OF B. XYLOPHILUS

Non-Final OA §101§102
Filed
Dec 04, 2024
Examiner
BERKE-SCHLESSEL, DAVID W
Art Unit
1651
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
ZHEJIANG A&F UNIVERSITY
OA Round
1 (Non-Final)
67%
Grant Probability
Favorable
1-2
OA Rounds
12m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
506 granted / 757 resolved
+6.8% vs TC avg
Strong +32% interview lift
Without
With
+31.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
39 currently pending
Career history
814
Total Applications
across all art units

Statute-Specific Performance

§101
9.6%
-30.4% vs TC avg
§103
37.8%
-2.2% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
25.0%
-15.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 757 resolved cases

Office Action

§101 §102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1 and 2 are rejected under 35 U.S.C. 101 because the claimed invention is directed to a product of nature without significantly more. The claim(s) recite(s) a deposited strain of Lagenidium juracyae. This judicial exception is not integrated into a practical application because the claims provide for the microbe, per se, and do not provide for additional elements that would provide for significantly more. Based upon the instant specification, and the prior art, L. juracyae is a naturally occurring nematocidal microbe. See Guo, et al (Pest Management Science, 81, 7102-7113, 2025), page 7102, “Abstract” section. Additionally, the specification does not suggest that the claimed microbe has been modified or mutated in any manner. As such, it seems clear that the claimed microbe, per se, is a product of nature. Since the claims provide for no additional limitations beyond the naturally occurring microbe, the composition, as a whole, must be a product of nature. See MPEP 2106, especially 2106.04(c). Claim Rejections - 35 USC § 102 It is noted that Guo, et al (CN 117165450A) is anticipating prior art; however, after looking at inventorship and ownership of the Chinese patent application, it appears as though this is not valid prior art under the 35 USC 102(a)(2) exception. Allowable Subject Matter Claims 3-8 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID W BERKE-SCHLESSEL whose telephone number is (571)270-3643. The examiner can normally be reached M-F 8AM-5:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DAVID W BERKE-SCHLESSEL/ Primary Examiner, Art Unit 1651
Read full office action

Prosecution Timeline

Dec 04, 2024
Application Filed
Aug 18, 2026
Non-Final Rejection mailed — §101, §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767971
METHOD TO PRODUCE RETINYL ACETATE
2y 8m to grant Granted Oct 20, 2026
Patent 12767969
ENZYME COMPOSITION FOR PREPARING Beta-NICOTINAMIDE MONONUCLEOTIDE, AND APPLICATION THEREOF
3y 0m to grant Granted Oct 20, 2026
Patent 12761209
Devices and Methods to Induce Adult type Maturation of Human Pluripotent Stem Cell Derived Cardiomyocytes
3y 7m to grant Granted Oct 13, 2026
Patent 12761210
PREDICTING EFFICACY OF OR RESISTANCE TO TREATMENT OF COLON CANCER
3y 3m to grant Granted Oct 13, 2026
Patent 12761208
IPSC-DERIVED ASTROCYTES AND METHODS OF USE THEREOF
3y 3m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
67%
Grant Probability
98%
With Interview (+31.5%)
2y 10m (~12m remaining)
Median Time to Grant
Low
PTA Risk
Based on 757 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month